Tuberculosis and survival of HIV-infected individuals by time since seroconversion

AIDS

Volumn 24, Issue 7, 2010, Pages 1067-1069

  Glynn, Judith R ^a   Murray, Jill ^b,c   Shearer, Stuart ^d   Sonnenberg, Pam ^e  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d GOLD FIELDS LIMITED   (South Africa)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID;

ARTICLE; DISEASE COURSE; DRUG EFFECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MORTALITY; PRIORITY JOURNAL; SEROCONVERSION; TUBERCULOSIS;

ADULT; DISEASE PROGRESSION; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; RISK FACTORS; SURVIVAL ANALYSIS; TUBERCULOSIS;

EID: 77950930239     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328337b100     Document Type: Article

References (15)

1. Del Amo J, Malin AS, Pozniak A, De Cock KM. Does tuberculosis accelerate the progression of HIV disease? Evidence from basic science and epidemiology. AIDS 1999; 13:1151-1158.
2. Whalen CC, Nsubuga P, Okwera A, Johnson JL, Hom DL, Michael NL, et al. Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda. AIDS 2000; 14:1219-1228.
3. Day JH, Grant AD, Fielding KL, Morris L, Moloi V, Charalambous S, et al. Does tuberculosis increase HIV load? J Infect Dis 2004; 190:1677-1684.
4. van der Sande MA, Schim van der Loeff MF, Bennett RC, Dowling M, Aveika AA, Togun TO, et al. Incidence of tuberculosis and survival after its diagnosis in patients infected with HIV-1 and HIV-2. AIDS 2004; 18:1933-1941.
5. Lopez-Gatell H, Cole SR, Hessol NA, French AL, Greenblatt RM, Landesman S, et al. Effect of tuberculosis on the survival of women infected with human immunodeficiency virus. Am J Epidemiol 2007; 165:1134-1142.
6. Lopez-Gatell H, Cole SR, Margolick JB, Witt MD, Martinson J, Phair JP, Jacobson LP. Effect of tuberculosis on the survival of HIV-infected men in a country with low tuberculosis incidence. AIDS 2008; 22:1869-1873.
7. Bucher HC, Griffith LE, Guyatt GH, Sudre P, Naef M, Sendi P, Battegay M. Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS 1999; 13:501-507.
8. Quigley MA, Mwinga A, Hosp M, Lisse I, Fuchs D, Porter JDH, Godfrey-Faussett P. Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS 2001; 15:215-222.
9. Johnson JL, Okwera A, Hom DL, Mayanja H, Mutuluuza Kityo C, Nsubuga P, et al. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS 2001; 15:2137-2147.
10. Todd J, Glynn JR, Marston M, Lutalo T, Biraro S, Mwita W, et al. Time from HIV seroconversion to death: a collaborative analysis of eight studies in six low and middle-income countries before highly active antiretroviral therapy. AIDS 2007; 21 (Suppl 6):S55-S63.
11. Glynn JR, Sonnenberg P, Nelson G, Bester A, Shearer S, Murray J. Survival from HIV-1 seroconversion in Southern Africa: a retrospective cohort study in nearly 2000 gold-miners over 10 years of follow-up. AIDS 2007; 21:625-632.
12. Glynn JR, Murray J, Bester A, Nelson G, Shearer S, Sonnenberg P. Effects of duration of HIV infection and secondary tuberculosis transmission on tuberculosis incidence in the South African gold mines. AIDS 2008; 22:1859-1867.
13. Murray J, Sonnenberg P, Nelson G, Bester A, Shearer S, Glynn JR. Cause of death and presence of respiratory disease at autopsy in an HIV-1 seroconversion cohort of southern African gold miners. AIDS 2007; 21 (Suppl 6):S97-S104.
14. CASCADE Collaboration. Impact of tuberculosis on HIV disease progression in persons with well documented time of HIV seroconversion. J Acquir Immune Defic Syndr 2003; 33:184-190.
15. Collaborative group on AIDS incubation and HIV survival including the CASCADE EU Concerted Action. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Lancet 2000; 355:1131-1137